Research stack

FOXO4-DRI Senolytic Research Protocol

Investigational senolytic peptide protocol targeting p53-FOXO4 interaction in senescent cells.

Component peptides

Investigational senolytic protocol targeting the p53-FOXO4 interaction in senescent cells.

The D-retro-inverso peptide disrupts FOXO4-p53 binding, releasing p53 to trigger apoptosis selectively in senescent cells.

FOXO4-DRI — 2-5 mg subcutaneous 3x per week for short pulses (community-reported range; human dosing undefined).

Last updated: 2026-09-15

Component peptides	FOXO4-DRI
Duration reported	3 weeks
Cycle pattern	Short-course pulses, 3 doses per week for 3 weeks
Difficulty	advanced
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.